Does Hormonal Therapy for Prostate Cancer Raise Mortality Risk?
SUMMARY AND COMMENT
Neoadjuvant androgen-deprivation therapy was associated with higher rates of all-cause mortality only in patients with coronary artery disease.
Reviewing:
Nanda A et al., JAMA 2009 Aug 26; 302:866
Breast Cancer in Childhood Cancer Survivors
SUMMARY AND COMMENT
Patients who received chest irradiation during treatment for childhood cancers had excess risk for breast cancer.
Reviewing:
Inskip PD et al., J Clin Oncol 2009 Aug 20; 27:3901
Budd-Chiari Syndrome: Causes and Treatments
SUMMARY AND COMMENT
Half of all cases were associated with myeloproliferative disorders, and half of all patients who received anticoagulation therapy did not require invasive procedures.
Reviewing:
Murad SD et al., Ann Intern Med 2009 Aug 4; 151:167
Gemcitabine Remains the Chemotherapy Standard for Pancreatic Cancer
SUMMARY AND COMMENT
Neither fixed-dose–rate infusion of gemcitabine nor the addition of oxaliplatin improved outcomes over standard gemcitabine therapy.
Reviewing:
Poplin E et al., J Clin Oncol 2009 Aug 10; 27:3778
New Therapy for Castration-Resistant Prostate Cancer
SUMMARY AND COMMENT
Use of the CYP17-inhibitor abiraterone was associated with declines in prostate-specific antigen levels.
Reviewing:
Attard G et al., J Clin Oncol 2009 Aug 10; 27:3742
Sunitinib for "Real World" Renal Cancer Patients
SUMMARY AND COMMENT
In an expanded-access study, sunitinib demonstrated efficacy in high-risk populations.
Reviewing:
Gore ME et al., Lancet Oncol 2009 Aug; 10:757
Choueiri TK and Bellmunt J., Lancet Oncol 2009 Aug; 10:740
The Gleason Score: Does Order of Pattern Numbers Matter?
SUMMARY AND COMMENT
As a prognostic marker for prostate cancer, 3 + 4 does not equal 4 + 3.
Reviewing:
Stark JR et al., J Clin Oncol 2009 Jul 20; 27:3459
Assessing Risk in Follicular Lymphoma
SUMMARY AND COMMENT
An update to the FL International Prognostic Index (FLIPI) for newly diagnosed disease
Reviewing:
Federico M et al., J Clin Oncol 2009 Aug 3
Hemolytic Uremic Syndrome
SUMMARY AND COMMENT
Mutations that impair thrombomodulin function occur in nearly 5% of patients with atypical HUS.
Reviewing:
Delvaeye M et al., N Engl J Med 2009 Jul 23; 361:345
Osteoporosis and Fracture in Men with Prostate Cancer
SUMMARY AND COMMENT
Denosumab increased bone-mineral density and lowered fracture incidence in men receiving androgen-deprivation therapy for nonmetastatic disease.
Reviewing:
Smith MR et al., N Engl J Med 2009 Aug 20; 361:745
Khosla S., N Engl J Med 2009 Aug 20; 361:818
